專利授權區國立清華大學國際產學營運總中心 Operations Center for Industry Collaboration

搜尋專利授權區

關鍵字

» 新增關鍵字

選單

專利授權區

專利授權區
專利名稱(中)	可同時口服傳遞疏水性小分子藥物和親水性小分子藥物的醫藥組合物
專利名稱(英)	PHARMACEUTICAL COMPOSITION FOR ORAL DELIVERY OF HYDROPHOBIC SMALL MOLECULE DRUG AND HYDROPHILIC SMALL MOLECULE DRUG CONCURRENTLY
專利家族	中華民國：I739450
專利權人	國立清華大學 100.00%
發明人	林柏諺,宋信文
技術領域	生化醫藥

專利摘要(中)
本發明提供一種醫藥組合物，其包含膜衣層以及藥物層。所述藥物層被膜衣層包覆，且藥物層包含有效劑量的疏水性小分子藥物、有效劑量的親水性小分子藥物、親脂性溶劑、酸性化合物和泡騰成分。當所述醫藥組合物經口服進入腸道時會產生二氧化碳氣泡，藉由二氧化碳氣泡膨脹、破裂引起的擾動，使醫藥組合物經自我乳化形成帶有疏水性小分子藥物的脂質油滴，並使親水性小分子藥物溶解於腸液中。藉此，所述醫藥組合物不需使用帶有毒性之載體，可經由口服同時傳遞疏水性小分子藥物和親水性小分子藥物，並可增加藥物的溶解度以提高口服生物利用度。

專利摘要(中)

本發明提供一種醫藥組合物，其包含膜衣層以及藥物層。所述藥物層被膜衣層包覆，且藥物層包含有效劑量的疏水性小分子藥物、有效劑量的親水性小分子藥物、親脂性溶劑、酸性化合物和泡騰成分。當所述醫藥組合物經口服進入腸道時會產生二氧化碳氣泡，藉由二氧化碳氣泡膨脹、破裂引起的擾動，使醫藥組合物經自我乳化形成帶有疏水性小分子藥物的脂質油滴，並使親水性小分子藥物溶解於腸液中。藉此，所述醫藥組合物不需使用帶有毒性之載體，可經由口服同時傳遞疏水性小分子藥物和親水性小分子藥物，並可增加藥物的溶解度以提高口服生物利用度。

專利摘要(英)
The invention relates to a pharmaceutical composition including an enteric layer and a drug layer. The drug layer includes a therapeutically effective amount of hydrophobic small molecule drugs, a therapeutically effective amount of hydrophilic small molecule drugs, a lipophilic solvent, an acidic compound and an effervescent ingredient. When the pharmaceutical composition enters the intestinal tract through oral administration, carbon dioxide bubbles are generated. The disturbance caused by the expansion and rupture of the carbon dioxide bubbles causes the pharmaceutical composition to self-emulsify to form lipid oil drops with the hydrophobic small molecule drugs, and the hydrophilic small molecule drugs are dissolved in the intestinal fluid. Therefore, the pharmaceutical composition does not need to use a toxic carrier, and can deliver the hydrophobic small molecule drug and the hydrophilic small molecule drug concurrently through oral administration, and can increase the solubility of the drug to improve oral bioavailability.

專利摘要(英)

The invention relates to a pharmaceutical composition including an enteric layer and a drug layer. The drug layer includes a therapeutically effective amount of hydrophobic small molecule drugs, a therapeutically effective amount of hydrophilic small molecule drugs, a lipophilic solvent, an acidic compound and an effervescent ingredient. When the pharmaceutical composition enters the intestinal tract through oral administration, carbon dioxide bubbles are generated. The disturbance caused by the expansion and rupture of the carbon dioxide bubbles causes the pharmaceutical composition to self-emulsify to form lipid oil drops with the hydrophobic small molecule drugs, and the hydrophilic small molecule drugs are dissolved in the intestinal fluid. Therefore, the pharmaceutical composition does not need to use a toxic carrier, and can deliver the hydrophobic small molecule drug and the hydrophilic small molecule drug concurrently through oral administration, and can increase the solubility of the drug to improve oral bioavailability.

聯絡資訊
承辦人姓名	劉千綺
承辦人電話	03-571-5131 #31181
承辦人Email	chienchi@mx.nthu.edu.tw